Zimbabwe has turned down a substantial American healthcare agreement worth 367 million US dollars (272 million pounds) over five years due to Washington's insistence on confidential data.
This move came to light after a official document dated December was disclosed, which showed President Emmerson Mnangagwa deemed the arrangement was "unbalanced".
A government representative later clarified that the US was seeking biological samples for research and profit but was not willing to share the resulting advantages from future treatments.
"We must now begin the difficult and regrettable task of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated over $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for more talks to reach a deal agreeable to both sides so the nation's critical HIV programme can be sustained.
Wider Background
This rejection comes after a comparable case in Kenya, where a high court blocked a similar health funding agreement after legal challenges were raised about the safety of Kenyans' medical information.
After returning to office recently, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had administered aid for the American government, but Trump stated its expenditure was "inefficient" and his government was seeking direct bilateral deals to enhance openness and accountability.
According to reports, 16 African countries have to date signed these new agreements, constituting more than $18.3bn in committed funds.
Specifics of the Declined Deal
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration might have yielded significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on antiretroviral therapy via US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data indefinitely, without any equivalent assurance of access to any medical innovations – like new medicines or tests – that might be developed from that shared data," Mangwana explained.
"Effectively, our country would provide the raw materials for medical research with no assurance that the final treatments would be available to our population should a future pandemic emerge."
National Interest and International Frameworks
He also pointed out that the American exit from the global health body and its pursuit of one-on-one deals were upending systems already set up via the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to deal with potential global health emergencies.
"This framework is intended to guarantee that when a country contributes its data, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
The government's concerns regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to further dialogue with our US partners on how subsequent co-operation could be arranged in a manner that respects the independence and interests of both nations."
Medical Community Reaction
A leading public health body expressed it acknowledged the official position, but suggested that talks should continue considering much of the nation's Aids initiatives depended on international support.
"In cases where technical issues arise, including those relating to data governance or agreement terms, these can frequently be addressed through technical clarification and negotiated safeguards," it commented.
The halted deal emphasises the ongoing tensions between accepting vital international aid and safeguarding national sovereignty in an ever more data-driven world.